The global peptic ulcer drugs market is anticipated to grow at a CAGR of around 3.3% during the forecast period 2020 to 2027 and to reach around US$ 39.7 Mn by 2027.
Market Dynamics
Increasing number of inpatients suffering from chronic diseases, increasing public-private partnership for drug development and government focus on delivering enhanced cares to patients are factors expected to drive the growth of global market. In the United States, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time. H pylori infection accounts for 90% of duodenal ulcers and 70-90% of gastric ulcers. In addition, high investment by major players and focus on development of novel products is expected to support the growth of target market.
Major players approach towards business expansion through strategic acquisition and partnership are factors expected to impact the growth of target market over the forecast period.
In 2020, Processa Pharmaceuticals Inc a global drug manufacturing pharmaceutical company signed a agreement with Yuhan Corp. in order to develop, manufacture and commercialize bowel disorder drug YH12852 worldwide. This agreement is expected to help the company to enhance the expansion of business and increase the revenue share.
In 2020, Cadila Pharmaceuticals Limited a drug manufacturing company launched Esomeprazole tablets for treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc. This product launch is expected to help the company to enhance the business profit and increase the customer base.
In 2019, AbbVie a research-based global biopharmaceutical company received approval for RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor. This is expected to help the company to increase the revenue share.
In 2016, Takeda Pharmaceutical Company received approval for its drug VONOSAP pack 400 and VONOSAP pack 800 to sell in Japan. This approval of product helped the company to enhance the business revenue.
Favorable business policies by the government and emergence of small and mid-size enterprises with innovative solutions are factors expected to boost the growth of target market.
However, factors such as high cost of drug development and stringent government regulations related to product approval are expected to hamper the growth of global peptic ulcer drugs market. In addition, side-effects of drug and changing pricing policies are factors expected to challenge the growth of target market.
Increasing investment by major players and development of medication with low side-effects are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing public-private partnerships for development of innovative products is expected to support the revenue growth of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global market due to rising number of patients suffering from chronic diseases. In addition, player’s presence in the country is increasing due to favorable business policies and large patient pool consuming medications this is expected to support the growth of target market.
Increasing acquisition and partnership activities by players in order to enhance the business is expected to boost the growth of regional market
Competitive Landscape
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Report coverage
|
Market
|
Global Peptic Ulcer Drugs Market
|
|
Analysis Period
|
2016 – 2027
|
|
Base Year
|
2019
|
|
Forecast Data
|
2020 – 2027
|
|
Market Stratification
|
Product, Indication, Distribution Channel and Geography
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
|
Peptic Ulcer Drugs Market Segment Analysis, 2019
The global peptic ulcer drugs market is segmented into product, indication, and distribution channel. The product segment is bifurcated into proton pump inhibitors, potassium-competitive acid blockers (P-CABs), antacids, H2- antagonists, antibiotics, and ulcer protective. Among product the proton pump inhibitors segment is expected to account for significant revenue share in the target market. The distribution channel segment is expected to hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce. Among the distribution channel the e-commerce segment is expected to witness faster growth in the target segment.
The players profiled in the report are GlaxoSmithKline plc., AstraZeneca plc., Takeda Pharmaceutical, Pfizer Inc., Abbvie Inc., Boehringer Ingelheim GmbH, Daewoong Pharmaceutical Co., Ltd., Eisai Co. Ltd., Cadila Healthcare Ltd., and Yuhan Corporation.
Market Segmentation
Market By Product
Proton Pump Inhibitors
Potassium-Competitive Acid Blockers (P-CABs)
Antacids
H2- Antagonists
Antibiotics
Ulcer Protective
Market By Indication
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)
Market By Distribution Channel
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
e-Commerce
Market By Region
North America
Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Peptic Ulcer Drugs
1.1. Definition and Scope
1.1.1. Definition of Peptic Ulcer Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Peptic Ulcer Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Peptic Ulcer Drugs Market By Product
1.2.3. Peptic Ulcer Drugs Market By Indicator
1.2.4. Peptic Ulcer Drugs Market By Distribution Channel
1.2.5. Peptic Ulcer Drugs Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Peptic Ulcer Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Peptic Ulcer Drugs Market
3.7. Value Chain Analysis
3.8. Cost Structure Analysis
3.8.1. Proportion of Manufacturing Cost Structure
3.8.1.1. Raw Material
3.8.1.2. Labor Cost
3.8.1.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Peptic Ulcer Drugs Major Manufacturers in 2019
CHAPTER 5. Peptic Ulcer Drugs Market By Product
5.1. Introduction
5.2. Peptic Ulcer Drugs Revenue By Product
5.2.1. Peptic Ulcer Drugs Revenue (US$ Mn) and Forecast, By Product, 2016-2027
5.2.2. Proton Pump Inhibitors
5.2.2.1. Proton Pump Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Potassium-Competitive Acid Blockers (P-CABs)
5.2.3.1. Potassium-Competitive Acid Blockers (P-CABs) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Antacids
5.2.4.1. Antacids Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. H2- Antagonists
5.2.5.1. H2- Antagonists Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Antibiotics
5.2.6.1. Antibiotics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.7. Ulcer Protective
5.2.7.1. Ulcer Protective Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Peptic Ulcer Drugs Market Revenue By Indicator
6.1. Introduction
6.2. Peptic Ulcer Drugs Revenue (US$ Mn) By Indicator
6.2.1. Peptic Ulcer Drugs Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
6.2.2. Gastritis
6.2.2.1. Gastritis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Gastric Ulcers
6.2.3.1. Gastric Ulcers Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Duodenal Ulcers
6.2.4.1. Duodenal Ulcers Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Gastroesophageal Reflux Disease (GERD)
6.2.5.1. Gastroesophageal Reflux Disease (GERD) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Peptic Ulcer Drugs Market By Distribution Channel
7.1. Introduction
7.2. Peptic Ulcer Drugs Revenue (US$ Mn) By Distribution Channel
7.2.1. Peptic Ulcer Drugs Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
7.2.2. Hospital Pharmacies
7.2.2.1. Hospital Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Private Clinics
7.2.3.1. Private Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Drug Stores
7.2.4.1. Drug Stores Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.5. Retail Pharmacies
7.2.5.1. Retail Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.6. e-Commerce
7.2.6.1. e-Commerce Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Peptic Ulcer Drugs Market By Country
8.1. North America Peptic Ulcer Drugs Overview
8.2. U.S.
8.2.1. U.S. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
8.2.2. U.S. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
8.2.3. U.S. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.3. Canada
8.3.1. Canada Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
8.3.2. Canada Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
8.3.3. Canada Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Peptic Ulcer Drugs Market By Country
9.1. Europe Peptic Ulcer Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.2.2. U.K. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
9.2.3. U.K. Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.3. Germany
9.3.1. Germany Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.3.2. Germany Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
9.3.3. Germany Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.4. France
9.4.1. France Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.4.2. France Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
9.4.3. France Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.5. Spain
9.5.1. Spain Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.5.2. Spain Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
9.5.3. Spain Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.6.2. Rest of Europe Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016-2027
9.6.3. Rest of Europe Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Peptic Ulcer Drugs Market By Country
10.1. Asia Pacific Peptic Ulcer Drugs Market Overview
10.2. China
10.2.1. China Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.2.2. China Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.2.3. China Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.3. Japan
10.3.1. Japan Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.3.2. Japan Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.3.3. Japan Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.4. India
10.4.1. India Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.4.2. India Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.4.3. India Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.5. Australia
10.5.1. Australia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.5.2. Australia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.5.3. Australia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.6.2. South Korea Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.6.3. South Korea Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.7.2. Rest of Asia-Pacific Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
10.7.3. Rest of Asia-Pacific Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Peptic Ulcer Drugs Market By Country
11.1. Latin America Peptic Ulcer Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.2.2. Brazil Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
11.2.3. Brazil Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.3.2. Mexico Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
11.3.3. Mexico Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.4.2. Rest of Latin America Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
CHAPTER 12. Middle East & Africa Peptic Ulcer Drugs Market By Country
12.1. Middle East & Africa Peptic Ulcer Drugs Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.2.2. Saudi Arabia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
12.2.3. Saudi Arabia Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.3. UAE
12.3.1. UAE Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.3.2. UAE Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
12.3.3. UAE Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.4.2. Rest of Middle East & Africa Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Indicator, 2016 - 2027
12.4.3. Rest of Middle East & Africa Peptic Ulcer Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
CHAPTER 13. PLAYER ANALYSIS OF PEPTIC ULCER DRUGS
13.1. Peptic Ulcer Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Peptic Ulcer Drugs Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreement
CHAPTER 14. COMPANY PROFILE
14.1. GlaxoSmithKline plc.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. GlaxoSmithKline plc. 2019 Peptic Ulcer Drugs Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Manufacturing Plant Footprint Analysis
14.2. AstraZeneca plc
14.3. Takeda Pharmaceutical
14.4. Pfizer Inc.
14.5. Abbvie Inc.
14.6. Boehringer Ingelheim GmbH
14.7. Daewoong Pharmaceutical Co., Ltd.
14.8. Eisai Co. Ltd.
14.9. Cadila Healthcare Ltd.
14.10. Yuhan Corporation
14.11. Others
